Bausch + Lomb Corporation operates as a global sentinel in the ophthalmic and vision care industries, dedicating its existence to the rather crucial task of ensuring humanity can, well, see. This venerable enterprise, tracing its lineage back to 1853, is a diversified pure-play eye health behemoth, meticulously developing, manufacturing, and commercializing products designed to protect, enhance, and, when necessary, restore that most precious of biological light sensors: the human eye.

Its operations are segmented into three critical areas. The Vision Care division equips the masses with contact lenses – from daily disposables to therapeutic variants – alongside an arsenal of lens care solutions, eye vitamins, and over-the-counter drops to combat everything from allergies to the existential dread of dry eye. Meanwhile, the Ophthalmic Pharmaceuticals segment wages chemical warfare against conditions like glaucoma, inflammation, and retinal diseases, offering a vast portfolio of prescription and OTC medications, arguably the largest in its niche. Finally, the Surgical segment provides the intricate medical devices, intraocular lenses, and specialized equipment required for delicate procedures like cataract and vitreoretinal surgeries, essentially performing ocular engineering.

The company’s entire raison d'être revolves around the intricate, often frustrating, biological machinery that allows us to interpret photons. They are the unsung heroes battling the relentless march of time and environmental assault on our most cherished sense, ensuring that the world doesn't devolve into an impressionistic blur for the masses. In essence, Bausch + Lomb builds and maintains the very infrastructure for human sight, a constant struggle against entropy's relentless march on our organic optical systems. Operating globally, with a significant presence across North America, Europe, Asia-Pacific, and Latin America, its products are sold in over 100 countries. A notable recent chapter in its long history was its spin-off from Bausch Health Companies in 2022, re-emerging as an independent public entity to continue its mission of illuminating our perceptual predicament.